Sls009 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sls009. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sls009 Today - Breaking & Trending Today

SLS009 Plus Venetoclax/Azacitidine Produces Responses in R/R AML, Including ASXL1+ Disease

SLS009 plus venetoclax and azacitidine elicited responses in patients with relapsed/refractory AML, particularly in those harboring ASXL1 mutations. ....

Angelos Stergiou , Life Sciences Group , Sciences Group , Hematologic Oncology , Acute Myeloid Leukemia ,

FDA Grants Fast Track Status to SLS009 for Relapsed/Refractory Acute Myeloid Leukemia

The FDA has granted fast track designation to SLS009 for use as a potential therapeutic option in patients with relapsed or refractory acute myeloid leukemia. ....

Angelos Stergiou , Life Sciences Group Inc , Life Sciences , Sciences Group , Relapsed Or Refractory Acute Myeloid Leukemia ,

FDA Grants Fast Track Designation to SLS009 for Relapsed/Refractory PTCL

The FDA has granted a fast track designation to SLS009 for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma. ....

Angelos Stergiou , Life Sciences , Life Sciences Group , Fast Track , Genfleet Therapeutics , Peripheralt Cell Lymphoma ,

SLS009 Plus Venetoclax/Azacitidine Displays Activity, Tolerability in Relapsed/Refractory AML

The addition of SLS009 to the combination of venetoclax and azacitidine produced anti-leukemic effects and was safe in patients with relapsed/refractory acute myeloid leukemia who did not respond or stopped responding to venetoclax-based therapies. ....

United States , Angelos Stergiou , Omer Jamy , Oneal Comprehensive Cancer Center , University Of Alabama At Birmingham , Bone Marrow Transplant Program , O Neal Comprehensive Cancer Center , Hematologic Oncology , Acute Myeloid Leukemia ,

FDA Awards Orphan Drug Designation to SLS009 in AML

The FDA has granted an orphan drug designation to SLS009 for the treatment of patients with acute myeloid leukemia. ....

Angelos Stergiou , Life Sciences Group , Orphan Drug Designation , Acute Myeloid Leukemia ,